Patents by Inventor Jean DA SILVA CORREIA

Jean DA SILVA CORREIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240043836
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.
    Type: Application
    Filed: November 23, 2022
    Publication date: February 8, 2024
    Applicant: ADARx Pharmaceuticals, Inc
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Sean Studer, Kimberly Fultz, Jean da Silva Correia
  • B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME
    Publication number: 20230391872
    Abstract: A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.
    Type: Application
    Filed: October 22, 2021
    Publication date: December 7, 2023
    Inventors: Martin Edward Dahl, Stephen Parmley, Marilyn Kehry, Jean da Silva Correia, Morena Shaw
  • ADAR DEPENDENT EDITING COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230272391
    Abstract: Disclosed herein are compositions and methods for recruiting and using ADAR. In some aspects, compositions and methods for targeting ADAR activity to a desired region, sequence, or nucleotide are disclosed. In some aspects, compositions and methods for increasing the efficiency of directed ADAR editing are disclosed.
    Type: Application
    Filed: July 30, 2021
    Publication date: August 31, 2023
    Applicant: ADARx Pharmaceutical, Inc.
    Inventors: Zhen Li, Rui Zhu, Jean da Silva Correia, Kimberly Fultz, Sean Studer, Sam Lear
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20220363759
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: May 3, 2022
    Publication date: November 17, 2022
    Inventors: Marilyn KEHRY, David J. KING, Jean DA SILVA CORREIA
  • Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 11352427
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 7, 2022
    Assignee: ANAPTYSBIO, INC.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20200148770
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: October 17, 2019
    Publication date: May 14, 2020
    Applicant: AnaptysBio, Inc.
    Inventors: Marilyn KEHRY, David J. KING, Jean DA SILVA CORREIA
  • Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
    Patent number: 10508149
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 17, 2019
    Assignee: AnaptysBio, Inc.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
    Publication number: 20180127500
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: April 1, 2016
    Publication date: May 10, 2018
    Inventors: Marilyn KEHRY, David J. KING, Jean DA SILVA CORREIA